Drugs / NPX887
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06240728 | Jan 2024 → Aug 2027 expected | metastatic malignant neoplasm | NextPoint Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPX887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06240728 ↗ |
| Action | Inhibit | “antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2)” NCT06240728 ↗ |
| Route | Intravenous | “Participants who are treated will receive an intravenous (IV) infusion of NPX887” NCT06240728 ↗ |
| Target | HHLA2 | “NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response.” NCT06240728 ↗ |